Flt3 Mutation Positive Relapsed Or Refractory Aml Therapeutics
1. Xospata patent expiration
Treatment: Treatment of acute myeloid leukemia (aml)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Nov, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(4 years from now) | |
| US11938133 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11944620 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938130 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938131 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938132 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| Orphan Drug Exclusivity(ODE-222) | Nov 28, 2025 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Dosage: TABLET
How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage
XOSPATA family patents
